ClassID:

20340

A61K31/421 - CPC Classification

Classification description:

Medicinal preparations containing organic active ingredients; Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole; Oxazoles 1,3-Oxazoles, e.g. pemoline, trimethadione

Recent Application in this class:
#1
20260144777
2026-05-28

2-PENTADECYL-2-OXAZOLINE IN ASSOCIATION WITH BUTYRIC ACID OR A SALT THEREOF IN THE TREATMENT OF EPILEPSY

#2
20260139030
2026-05-21

CHIMERIC PROTEINS FOR TREATING CUTANEOUS INFLAMMATION

#3
20260137661
2026-05-21

PPAR-ALPHA/GAMMA AGONIST FOR USE IN THE TREATMENT OF LIVER FAILURE

#4
20260124201
2026-05-07

CYCLOPENTANE COMPOUND

#5
20260124200
2026-05-07

METHOD OF TREATING NEURODEGENERATIVE DISEASES

#6
20260108501
2026-04-23

PHARMACEUTICAL COMBINATION COMPRISING PONESIMOD

#7
20260108497
2026-04-23

OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION

#8
20260108496
2026-04-23

METHODS FOR REPROGRAMING EXHAUSTED T CELLS AND BOOSTING IMMUNE CHECKPOINT BLOCKADE THERAPY FOR CANCER

#9
20260097046
2026-04-09

PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS

#10
20260085034
2026-03-26

N-(BENZHYDRYL)CYCLOALKYLCARBOXAMIDE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF

#11
20260083702
2026-03-26

INHALATION FORMULATION FOR TREATING IPF DISEASE AND PREPARATION METHOD THEREFOR

#12
20260054267
2026-02-26

PRODUCTION OF ENCAPSULATED NANOPARTICLES AT COMMERCIAL SCALE

#13
20260027123
2026-01-29

Compositions for Modulating Lipoxygenase and Methods of Using Same

#14
20260021075
2026-01-22

2-PENTADECYL-2-OXAZOLINE AS AN OPIOID ADJUVANT TO PREVENT OR TREAT HYPERALGESIA

#15
20260007639
2026-01-08

COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS

#16
20250388595
2025-12-25

MODULATORS OF EUKARYOTIC INITIATION FACTOR 2B, COMPOSITIONS AND METHODS

#17
20250388541
2025-12-25

HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN

#18
20250388536
2025-12-25

3-ALKYNYL CARBOXAMIDES AS AEP MODULATORS

#19
20250381250
2025-12-18

COLLAGEN MACROPEPTIDE PREPARATIONS AND USES THEREOF

#20
20250375475
2025-12-11

PHARMACEUTICAL COMPOSITION AND METHODS FOR MODULATING INFLAMMATION AND OXIDATIVE STRESS

#21
20250340537
2025-11-06

PHARMACEUTICALLY ACTIVE COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING PENDRIN

#22
20250320184
2025-10-16

SARM1 MODULATORS, PREPARATIONS, AND USES THEREOF

#23
20250319054
2025-10-16

Synthetic Eicosanoid Analogues for the Treatment and Prevention of Diseases Associated with Increased GDF15 Plasma Concentration

#24
20250313539
2025-10-09

Alpha, Beta-UNSATURATED AMIDE COMPOUND, AND PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF

#25
20250289789
2025-09-18

REVERSIBLE LYSINE COVALENT MODIFIERS OF CDK2 AND USES THEREOF

#26
20250288559
2025-09-18

PREP BINDING LIGANDS

#27
20250228865
2025-07-17

COMPOUNDS FOR ENHANCING READ THROUGH OF GENES CONTAINING PREMATURE TERMINATION CODONS AND METHODS FOR MAKING AND USING THE SAME

#28
20250214930
2025-07-03

TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA

#29
20250188068
2025-06-12

AMIDO CYCLOPROPYL DERIVATIVES AS LPA RECEPTOR INHIBITORS

#30
20250177354
2025-06-05

THERAPEUTIC COMBINATIONS, COMPOSITIONS, AND METHODS FOR DESIGNING AND PRODUCING ENTACTOGENIC MINDSTATES

#31
20250163006
2025-05-22

New Coolants, and Preparations Containing Same

#32
20250144078
2025-05-08

THIOSTREPTON-INSPIRED COMPOUNDS FOR TREATMENT OF CANCER AND PREPARATION THEREOF

#33
20250129012
2025-04-24

ANTI-INFLAMMATORY AND ANALGESIC COMPOUNDS AND USE THEREOF

#34
20250122253
2025-04-17

REGULATING MICROTUBULE DYNAMICS AS A THERAPEUTIC TARGET FOR NERVE REPAIR

#35
20250122152
2025-04-17

KAT6 Inhibitors

#36
20250099434
2025-03-27

METHODS OF TREATING AMYLOID RELATED BRAIN DISORDERS USING NOVEL COMPOUNDS AND ANTIBODIES

#37
20250084043
2025-03-13

FORMULATION OF METAXALONE

#38
20250082781
2025-03-13

METHODS OF LOWERING BLOOD GLUCOSE AND TREATING TYPE 2 DIABETES BY ACTIVATION OF PDE4D3

#39
20250049764
2025-02-13

Compositions and Methods of Treating Cardiac Fibrosis with Ifetroban

#40
20250049720
2025-02-13

Method for improving the dissolution profile of a biologically active material

#41
20250017907
2025-01-16

METHOD FOR PREVENTING AND/OR TREATING LIVER FIBROSIS BY USING 6-METHOXYBENZOXAZOLINONE AND COIX LACHRYMA-JOBI L. EXTRACT COMPRISING 6-METHOXYBENZOXAZOLINONE

#42
20240398731
2024-12-05

C5AR INHIBITORS FOR USE IN THE TREATMENT OF CHEMOTHERAPY-INDUCED IATROGENIC PAIN

#43
20240382464
2024-11-21

Manufacturing Process for Metaxalone Tablets

#44
20240374573
2024-11-14

IMIDAZOLE CONTAINING COMPOUNDS, DERIVATIVES THEREFORE, AND USES THEREOF

#45
20240366595
2024-11-07

PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS

#46
20240366573
2024-11-07

OINTMENT CONTAINING AN OXAZOLE COMPOUND

#47
20240366538
2024-11-07

Hepatitis B Antiviral Agents

#48
20240336642
2024-10-10

INHIBITORS OF 12/15-LIPOXYGENASE

#49
20240335376
2024-10-10

GASTRORETENTIVE DOSAGE FORMS FOR SUSTAINED DRUG DELIVERY

#50
20240327334
2024-10-03

Covalent Inhibitors As Antiviral Agents

#51
20240325487
2024-10-03

COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT

#52
20240325355
2024-10-03

REDUCED DOSE METAXALONE FORMULATIONS

#53
20240307384
2024-09-19

PYRAZINE-CONTAINING COMPOUND

#54
20240307382
2024-09-19

MODULATORS OF THE INTEGRATED STRESS PATHWAY

#55
20240301417
2024-09-12

METHODS AND COMPOSITIONS FOR TREATING CHRONIC LIVER DISEASE AND HEPATOCELLULAR CARCINOMA

#56
20240287052
2024-08-29

NOVEL OXAZOLE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ALLERGIC DISEASES COMPRISING THE SAME

#57
20240279215
2024-08-22

NAMPT MODULATORS

#58
20240277658
2024-08-22

NLRP3 ACTIVATORS FOR USE IN THE TREATMENT OF INFECTIOUS DISEASES OR CANCER BY ACTIVATING NLRP3 INFLAMMASOME

#59
20240277649
2024-08-22

FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF CONDITIONS RELATED TO METABOLIC SYNDROME

#60
20240269121
2024-08-15

METHODS OF REDUCING ACNE AND ROSACEA RELAPSE RATE AND SEVERITY

#61
20240254079
2024-08-01

Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha

#62
20240246913
2024-07-25

2-CARBOXYL-INDOLE INHIBITORS OF METALLO-BETA-LACTAMASES

#63
20240246908
2024-07-25

TEAD INHIBITORS

#64
20240238374
2024-07-18

METHODS AND COMPOSITIONS FOR INDUCING BROWN ADIPOGENESIS

#65
20240226035
2024-07-11

Precision Medicine Approach to Treating Parkinson's Disease with a Monoamine Oxidase Inhibitor, an Antioxidant, or Both

#66
20240216364
2024-07-04

STRONG POTENTIATION OF TLR3 AGONISTS EFFECTS USING FXR AGONISTS AS A COMBINED TREATMENT

#67
20240216340
2024-07-04

REDUCED DOSE METAXALONE FORMULATIONS

#68
20240197687
2024-06-20

METHODS OF TREATING NEUROINFLAMMATION AND INHIBITING MONOAMINE OXIDASE-A AND RESTORING/UPREGULATING/INCREASING IL-13 AND AND PGC-1 BY ADMINISTERING ORAL DOSAGE FORM CONTAINING MICRONIZED AND NONMICRONIZED PARTICULATE METAXALONE, ALGINIC ACID AND PROPYLENE GLYCOL ALGINATE

#69
20240197666
2024-06-20

DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC)

#70
20240173307
2024-05-30

MODULATORS OF THE INTEGRATED STRESS PATHWAY

#71
20240156872
2024-05-16

Use of Chaperone-Mediated Autophagy Activators For Treating Or Preventing Blood Cancers And Myelodysplastic Syndromes And Enriching Hematopoietic Stem Cell Populations

#72
20240156790
2024-05-16

COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS

#73
20240150304
2024-05-09

FORMULATION OF METAXALONE

#74
20240148699
2024-05-09

OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION

#75
20240139214
2024-05-02

AGENT FOR SUPPRESSING IL-31 PRODUCTION AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME

#76
20240139161
2024-05-02

PHARMACEUTICAL COMBINATION COMPRISING PONESIMOD

#77
20240139152
2024-05-02

HBV INHIBITOR AND ITS USE

#78
20240122941
2024-04-18

THERAPY BASED ON SYNTHETIC LETHALITY IN SWI/SNF COMPLEX-DYSFUNCTION CANCER

#79
20230404916
2023-12-21

Gastroretentive dosage forms for sustained drug delivery

#80
20230381146
2023-11-30

SUBSTITUTED HETEROARYL COMPOUNDS AND USE THEREOF

#81
20230364115
2023-11-16

NOVEL PSYCHEDELIC COMPOSITIONS, DELIVERY SYSTEMS AND THERAPEUTIC USES THEREOF

#82
20230356232
2023-11-09

PRODUCTION OF ENCAPSULATED NANOPARTICLES AT COMMERCIAL SCALE

#83
20230355636
2023-11-09

COMBINATIONS OF 15-PGDH INHIBITORS WITH CORTICOSTEROIDS AND/OR TNF INHIBITORS AND USES THEREOF

#84
20230355590
2023-11-09

ISOXAZOLINE-SUBSTITUTED BENZAMIDE COMPOUND AND PESTICIDE

#85
20230346797
2023-11-02

INHIBITORS OF THE PLASMODIAL SURFACE ANION CHANNEL AS ANTIMALARIALS

#86
20230320987
2023-10-12

LIPID NANOPARTICLES AND LIPOSOMES

#87
20230312537
2023-10-05

Neprilysin inhibitors

#88
20230310387
2023-10-05

Reduced dose metaxalone formulations

#89
20230285372
2023-09-14

Pharmaceutical use of (E)-3-arylheterocyclylprop-2-enoic acid derivatives

#90
20230285282
2023-09-14

OCULAR IMPLANT CONTAINING AN ACTIVE INGREDIENT

#91
20230270726
2023-08-31

Compositions and methods of treating cardiac fibrosis with ifetroban

#92
20230241012
2023-08-03

Hepatitis B antiviral agents

#93
20230226062
2023-07-20

HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS

#94
20230190689
2023-06-22

METHODS AND COMPOSITIONS FOR INDUCING BROWN ADIPOGENESIS

#95
20230181540
2023-06-15

COMPOSITIONS AND METHODS FOR ACTIVATING SIGNALING THROUGH THE CB2 CANNABINOID RECEPTOR FOR TREATING AND PREVENTING LYSOSOMAL STORAGE DISEASES AND DISORDERS

#96
20230133244
2023-05-04

Method for the Production of Commercial Nanoparticle and Microparticle Powders

#97
20230127304
2023-04-27

NEW INHIBITORS FOR THE KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION

#98
20230119013
2023-04-20

N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS

#99
20230083885
2023-03-16

MODULATORS OF INTEGRATED STRESS RESPONSE PATHWAY

#100
20230055339
2023-02-23

COMPOSITION COMPRISING RILMENIDINE COMPOUND AS ACTIVE INGREDIENT FOR TREATMENT OF FRAGILE X SYNDROME OR RELATED DEVELOPMENTAL DISABILITY

#101
20230047905
2023-02-16

COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY

#102
20230041576
2023-02-09

METHODS AND MATERIALS FOR INHIBITING NF-kB ACTIVITY

#103
20230021476
2023-01-26

Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha

#104
20220411433
2022-12-29

Modulators of eukaryotic initiation factor 2B, compositions and methods

#105
20220347176
2022-11-03

Phenyl-sulfamoyl.benzoyc acids as ERAP1 modulators

#106
20220347173
2022-11-03

METHODS OF TREATING LIVER FIBROSIS USING CALPAIN INHIBITORS

#107
20220304984
2022-09-29

AMINO ACID TRANSPORT INHIBITORS AND THE USES THEREOF

#108
20220296581
2022-09-22

Immunomodulation by IAP Inhibitors

#109
20220280527
2022-09-08

TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT

#110
20220265645
2022-08-25

Pyrazine-containing compound

#111
20220265613
2022-08-25

OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION

#112
20220249446
2022-08-11

Composition Comprising at Least One Oxazoline for Inhibiting the Growth of Malassezia Yeasts Involved in Cradle Cap, in Particular

#113
20220235017
2022-07-28

FORMULATION OF METAXALONE

#114
20220218604
2022-07-14

GASTRORETENTIVE DOSAGE FORMS FOR SUSTAINED DRUG DELIVERY

#115
20220202780
2022-06-30

PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS COMPRISING INHIBITORS OF THE ANDROGEN RECEPTOR AND USES THEREOF

#116
20220193041
2022-06-23

NOVEL COMPOUND AND METHOD FOR PREVENTING OR TREATING OF RESPIRATORY DISEASES COMPRISING THE SAME AS AN ACTIVE INGREDIENT

#117
20220184035
2022-06-16

HBV inhibitor and its use

#118
20220175818
2022-06-09

Inhibition of Monoamine Oxidase Subtype A (MAOA) Mitigates Cardiovascular Calcification

#119
20220143186
2022-05-12

SOLIDIFICATION OR CRYSTALLISATION METHOD

#120
20220143135
2022-05-12

Inhibitors of Bcl-2

#121
20220142985
2022-05-12

AGENTS FOR TREATMENT OF ALCOHOL USE DISORDER

#122
20220118155
2022-04-21

Synergistically cooperative compositions useful for soft tissue augmentation, drug delivery and related fields

#123
20220117944
2022-04-21

OINTMENT CONTAINING AN OXAZOLE COMPOUND

#124
20220106300
2022-04-07

Neprilysin inhibitors

#125
20220081403
2022-03-17

OXAZOLIDINONE COMPOUNDS AND METHODS OF USE THEREOF AS ANTIBACTERIAL AGENTS

#126
20220081390
2022-03-17

FARNESOID X RECEPTOR AGONISTS AND USES THEREOF

#127
20220079928
2022-03-17

LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONIST AND PREPARATION METHOD THEREFOR

#128
20220062281
2022-03-03

INHIBITORS TO TARGET HIV-1 NEF-CD80/CD86 INTERACTIONS FOR THERAPEUTIC INTERVENTION

#129
20220023265
2022-01-27

USE OF INHIBITORS OF PHOSPHATASE ACTIVITY OF SOLUBLE EPOXIDE FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES

#130
20220000863
2022-01-06

Pyrazine-containing compound

#131
20210403442
2021-12-30

Novel formulation of metaxalone

#132
20210401809
2021-12-30

PHARMACEUTICAL COMPOUNDS

#133
20210401808
2021-12-30

(2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid

#134
20210401753
2021-12-30

Method for improving the dissolution profile of a biologically active material

#135
20210393599
2021-12-23

MODULATORS OF THE INTEGRATED STRESS PATHWAY

#136
20210393549
2021-12-23

New use of R-enantiomer of adrenergic beta 2 receptor agonists for treatment of inflammatory bowel disease and its extra intestinal manifestations

#137
20210369680
2021-12-02

METHODS OF TREATING DISEASES AND DISORDERS RESULTING FROM BETA CORONAVIRUS INFECTION

#138
20210369664
2021-12-02

PROPHYLACTIC OR THERAPEUTIC AGENT FOR PULMONARY HYPERTENSION WHICH COMPRISES PPAR? AGONIST

#139
20210353569
2021-11-18

Analogs of CYP-Eicosanoids for Use in Treating or Preventing a Disorder Associated with Neovascularization and/or Inflammation

#140
20210347749
2021-11-11

P62 ligand compound, and composition for preventing, ameliorating or treating proteinopathies comprising the same

#141
20210346364
2021-11-11

Oxazolidinones as TarO inhibitors

#142
20210340114
2021-11-04

HETEROCYCLIC COMPOUND

#143
20210317079
2021-10-14

Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2α

#144
20210299253
2021-09-30

AUTOTAC chimeric compound, and composition for preventing, ameliorating or treating diseases through targeted protein degradation comprising the same

#145
20210299107
2021-09-30

COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS

#146
20210299070
2021-09-30

METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY

#147
20210290623
2021-09-23

METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS

#148
20210290612
2021-09-23

Methods of treating PACS1 and PACS2 syndromes

#149
20210283077
2021-09-16

Hepatitis B antiviral agents

#150
20210277007
2021-09-09

Hetero-halo inhibitors of histone deacetylase

#151
20210269399
2021-09-02

MODULATORS OF THE INTEGRATED STRESS PATHWAY

#152
20210260598
2021-08-26

PRODUCTION OF ENCAPSULATED NANOPARTICLES AT COMMERCIAL SCALE

#153
20210244677
2021-08-12

Electrospun fibers for a local release of an anti-inflammatory drug and a promyelinating drug

#154
20210238151
2021-08-05

Oxazolidinone hydroxamic acid derivatives

#155
20210236469
2021-08-05

Fatty acids as anti-inflammatory agents

#156
20210236421
2021-08-05

Gastroretentive dosage forms for sustained drug delivery

#157
20210230176
2021-07-29

Hepatitis B antiviral agents

#158
20210220408
2021-07-22

ARYL HYDROCARBON RECEPTOR ANTAGONISTS AND METHODS OF USE

#159
20210212996
2021-07-15

METHODS OF TREATING NEURODEGENERATIVE DISEASES USING INDANE ACETIC ACID DERIVATIVES WHICH PENETRATE THE BLOOD BRAIN BARRIER

#160
20210212995
2021-07-15

Metaxalone formulations

#161
20210212993
2021-07-15

Use of prostacyclin antagonists for treating ocular surface nociception

#162
20210186947
2021-06-24

TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION

#163
20210186917
2021-06-24

TREM2 AGONISTS FOR THE STIMULATION OF MICROGLIA AND METHODS OF IDENTIFICATION

#164
20210169838
2021-06-10

Novel class of compounds for the treatment of cardiovascular disease.

#165
20210163399
2021-06-03

NOVEL P62 LIGAND COMPOUND, AND COMPOSITION FOR PREVENTING, AMELIORATING OR TREATING PROTEINOPATHIES COMPRING THE SAME

#166
20210154138
2021-05-27

Methods for preparing stabilized amorphous drug formulations using acoustic fusion

#167
20210137895
2021-05-13

Compositions and Methods of Treating Cardiac Fibrosis with Ifetroban

#168
20210121476
2021-04-29

INHIBITORS OF THE PLASMODIAL SURFACE ANION CHANNEL AS ANTIMALARIALS

#169
20210113560
2021-04-22

METHOD OF TREATING FIBROTIC DISEASE

#170
20210101873
2021-04-08

FORMULATION OF METAXALONE

#171
20210085505
2021-03-25

Compositions and methods for treating severe pain

#172
20210061777
2021-03-04

OXAZOLIDINONE COMPOUNDS AND METHODS OF USE THEREOF AS ANTIBACTERIAL AGENTS

#173
20210038597
2021-02-11

Pyrazine-containing compound

#174
20210032195
2021-02-04

Farnesoid X receptor agonists and uses thereof

#175
20210022999
2021-01-28

Gastroretentive dosage forms for sustained drug delivery

#176
20210009682
2021-01-14

REDUCING CUTANEOUS SCAR FORMATION AND TREATING SKIN CONDITIONS

#177
20200405693
2020-12-31

REDUCED DOSE METAXALONE FORMULATIONS

#178
20200397725
2020-12-24

C5aR inhibitors for use in the treatment of chemotherapy-induced iatrogenic pain

#179
20200390710
2020-12-17

Method for the Production of Commercial Nanoparticle and Microparticle Powders

#180
20200376090
2020-12-03

COMBINED COLLAGEN NSAID ANALGESIC DOSAGE REGIMEN

#181
20200375903
2020-12-03

Method for improving the dissolution profile of a biologically active material

#182
20200368228
2020-11-26

Pyrazine-containing compound

#183
20200345727
2020-11-05

MODULATORS OF THE INTEGRATED STRESS PATHWAY

#184
20200345714
2020-11-05

Immunomodulation by IAP inhibitors

#185
20200345697
2020-11-05

USE OF PROSTACYCLIN ANTAGONISTS FOR TREATING OCULAR SURFACE NOCICEPTION

#186
20200345676
2020-11-05

Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome

#187
20200337998
2020-10-29

Gastroretentive dosage forms for sustained drug delivery

#188
20200308123
2020-10-01

Novel formulation of metaxalone

#189
20200308109
2020-10-01

FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF

#190
20200283422
2020-09-10

Neprilysin inhibitors

#191
20200281900
2020-09-10

(2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid

#192
20200261436
2020-08-20

Oxazolidinones as taro inhibitors

#193
20200261359
2020-08-20

Gastroretentive dosage forms for sustained drug delivery

#194
20200247814
2020-08-06

Hetero-halo inhibitors of histone deacetylase

#195
20200237728
2020-07-30

Chemotherapeutic methods for treating low-proliferative disseminated tumor cells

#196
20200223817
2020-07-16

Method of treating or preventing Ras-mediated diseases

#197
20200222406
2020-07-16

METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS

#198
20200199143
2020-06-25

Hepatitis B antiviral agents

#199
20200171006
2020-06-04

OINTMENT CONTAINING AN OXAZOLE COMPOUND

#200
20200157062
2020-05-21

Heterocyclic compound

#201
20200155512
2020-05-21

Compositions and methods of treating cardiac fibrosis with ifetroban

#202
20200155511
2020-05-21

ISOXAZOLINE-SUBSTITUTED BENZAMIDE COMPOUND AND PESTICIDE

#203
20200147091
2020-05-14

COMPOSITIONS FOR MODULATING PD-1 SIGNAL TRANSDUCTION

#204
20200121665
2020-04-23

PPAR GAMMA MODULATORS FOR TREATING CYSTIC DISEASES

#205
20200078340
2020-03-12

OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION

#206
20200069655
2020-03-05

Pharmaceutical combination comprising ponesimod

#207
20200061073
2020-02-27

Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof

#208
20200054558
2020-02-20

AEROSOL DELIVERY SYSTEMS, COMPOSITIONS AND METHODS

#209
20200038475
2020-02-06

Compounds and methods for inhibiting phosphate transport

#210
20200000777
2020-01-02

Isoxazoline-substituted benzamide compound and pesticide

#211
20190365718
2019-12-05

Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase

#212
20190358338
2019-11-28

Hybrid telodendrimers

#213
20190350905
2019-11-21

Pharmaceutical compounds

#214
20190350886
2019-11-21

Compositions and methods for treating severe pain

#215
20190336484
2019-11-07

IL-8 INHIBITORS FOR USE IN THE TREATMENT OF SOME UROLOGICAL DISORDERS

#216
20190336483
2019-11-07

Autophagy enhancer and use thereof

#217
20190330167
2019-10-31

ACTIVATORS OF HIV LATENCY

#218
20190308934
2019-10-10

Prodrugs of Chlorokynurenines

#219
20190292161
2019-09-26

GP130 modulators

#220
20190276442
2019-09-12

Neprilysin inhibitors

#221
20190275009
2019-09-12

Fatty acids as anti-inflammatory agents

#222
20190275008
2019-09-12

Triazole furan compounds as agonists of the APJ receptor

#223
20190269659
2019-09-05

(2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid

#224
20190255022
2019-08-22

WOUND-HEALING AGENT

#225
20190248753
2019-08-15

Oxazolidinone compounds and methods of use thereof as antibacterial agents

#226
20190247364
2019-08-15

Compositions and methods of treating cardiac fibrosis with ifetroban

#227
20190231751
2019-08-01

TREATMENT OF FIBROTIC DISORDERS WITH JUN N-TERMINAL KINASE INHIBITORS

#228
20190225684
2019-07-25

REDUCING CUTANEOUS SCAR FORMATION AND TREATING SKIN CONDITIONS

#229
20190224212
2019-07-25

Nrf2 regulators

#230
20190224145
2019-07-25

Use of a combination of Adelmidrol and hyaluronic acid in the treatment of pain caused by osteoarthritis and epithelial dysfunctions

#231
20190201410
2019-07-04

TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT

#232
20190194135
2019-06-27

Modulators of the integrated stress pathway

#233
20190193085
2019-06-27

PRODUCTION OF ENCAPSULATED NANOPARTICLES AT COMMERCIAL SCALE

#234
20190192630
2019-06-27

MUTATED FIBROBLAST GROWTH FACTOR (FGF) 1 AND METHODS OF USE

#235
20190183863
2019-06-20

Compounds For The Treatment Of Neuromuscular Disorders

#236
20190183818
2019-06-20

Inhibition of sphingosine 1-phosphate receptor for treatment and prevention of lymphedema

#237
20190177271
2019-06-13

FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF

#238
20190167767
2019-06-06

Therapeutic combinations to treat red blood cell disorders

#239
20190152930
2019-05-23

FORMULATION OF METAXALONE

#240
20190144432
2019-05-16

Metallo-beta-lactamase inhibitors

#241
20190125729
2019-05-02

NOVEL TRAPS IN THE TREATMENT OF MACULAR DEGENERATION

#242
20190119225
2019-04-25

Heterocyclic compound

#243
20190117607
2019-04-25

Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome

#244
20190117597
2019-04-25

ANALOGS OF CYP-EICOSANOIDS FOR USE IN TREATING OR PREVENTING A DISORDER ASSOCIATED WITH NEOVASCULARIZATION AND/OR INFLAMMATION

#245
20190111055
2019-04-18

Use of pharmaceutical composition for the treatment of skin erythema in poikilodermas

#246
20190111031
2019-04-18

Analgesic compounds

#247
20190092755
2019-03-28

Compounds for treatment of cancer

#248
20190091243
2019-03-28

FIXED DOSE COMBINATION FOR PAIN RELIEF WITHOUT EDEMA

#249
20190084994
2019-03-21

Hepatitis B antiviral agents

#250
20190076508
2019-03-14

Lysosomal acid lipase and PPAR gamma ligands as immune therapies for cancer treatment

#251
20190070201
2019-03-07

FIXED DOSE COMBINATION FOR PAIN RELIEF WITHOUT EDEMA

#252
20190070151
2019-03-07

OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION

#253
20190060286
2019-02-28

Chemotherapeutic Methods

#254
20190060258
2019-02-28

Hepatitis B antiviral agents

#255
20190038588
2019-02-07

NOVEL CLASS OF COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE

#256
20190031628
2019-01-31

Aminoazole derivative

#257
20190022027
2019-01-24

Reprogramming-based models of neurodevelopmental disorders and uses thereof

#258
20190002402
2019-01-03

IDO inhibitors

#259
20190000810
2019-01-03

Ointment containing an oxazole compound

#260
20180369171
2018-12-27

PPAR-alpha agonist treatment of neuropsychiatric disorders

#261
20180364216
2018-12-20

Choroidal neovascularization suppressor or drusen formation suppressor, and method for assessing or screening for same

#262
20180344704
2018-12-06

Compositions and methods of treating cardiac fibrosis with ifetroban

#263
20180338924
2018-11-29

SOLID PHARMACEUTICAL DOSAGE FORM FOR RELEASE OF AT LEAST ONE ACTIVE PHARMACEUTICAL INGREDIENT IN THE ORAL CAVITY

#264
20180327351
2018-11-15

PRODRUGS OF CHLOROKYNURENINES

#265
20180318380
2018-11-08

Methods of treating muscular dystrophy

#266
20180318266
2018-11-08

Isoxazoline-substituted benzamide compound and pesticide

#267
20180290987
2018-10-11

OXAZOLIDINONE COMPOUNDS AND METHODS OF USE THEREOF AS ANTIBACTERIAL AGENTS

#268
20180289664
2018-10-11

Benzhydrol derivatives for the management of conditions related to hypoxia inducible factors

#269
20180282263
2018-10-04

Farnesoid X receptor agonists and uses thereof

#270
20180264003
2018-09-20

Inhibitors of the plasmodial surface anion channel as antimalarials

#271
20180263989
2018-09-20

THERAPEUTIC APPROACHES FOR TREATING PARKINSON'S DISEASE

#272
20180263959
2018-09-20

Methods of treating muscular dystrophy

#273
20180263917
2018-09-20

SINGLE SOLID ORAL DOSAGE FORMS FOR TREATING HELICOBACTER PYLORI INFECTION AND DUODENAL ULCER DISEASE

#274
20180251433
2018-09-06

Novel formulation of metaxalone

#275
20180244656
2018-08-30

Metallo-beta-lactamase inhibitors

#276
20180237423
2018-08-23

Neprilysin inhibitors

#277
20180237404
2018-08-23

Heterocyclic compound

#278
20180235958
2018-08-23

Pancreatitis treatment

#279
20180228774
2018-08-16

(2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid

#280
20180208586
2018-07-26

Substituted oxazoles for the treatment of cancer

#281
20180207124
2018-07-26

Anticancer agent comprising aminoacetonitrile compound as active ingredient

#282
20180200230
2018-07-19

METHODS OF TREATING NEURODEGENERATIVE DISEASES USING INDANE ACETIC ACID DERIVATIVES WHICH PENETRATE THE BLOOD BRAIN BARRIER

#283
20180193418
2018-07-12

MUTATED FIBROBLAST GROWTH FACTOR (FGF) 1 AND METHODS OF USE

#284
20180193338
2018-07-12

NEPRILYSIN INHIBITORS

#285
20180179190
2018-06-28

Metallo-β-lactamase inhibitors

#286
20180177784
2018-06-28

HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS

#287
20180170863
2018-06-21

ROR gamma (RORγ) modulators

#288
20180169662
2018-06-21

PRODUCTION OF ENCAPSULATED NANOPARTICLES AT COMMERCIAL SCALE

#289
20180169110
2018-06-21

NRF2 regulators

#290
20180169018
2018-06-21

Method for improving the dissolution profile of a biologically active material

#291
20180153898
2018-06-07

COMPOSITIONS FOR MODULATING PD-1 SIGNAL TRANSDUCTION

#292
20180153861
2018-06-07

METHOD OF TREATING ATHEROSCLEROSIS IN HIGH TRIGLYCERIDE SUBJECTS

#293
20180153860
2018-06-07

METHODS OF DOSE ADMINISTRATION FOR TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES

#294
20180153859
2018-06-07

METHODS OF TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES BASED ON APOE4 GENOTYPE

#295
20180148422
2018-05-31

FORMULATION OF METAXALONE

#296
20180148418
2018-05-31

AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES

#297
20180118661
2018-05-03

Compounds and methods for the treatment of neurodegenerative diseases

#298
20180117015
2018-05-03

Targeting metabolic adaptive responses to chemotherapy

#299
20180117013
2018-05-03

METHODS OF TREATING LIVER DISEASE USING INDANE ACETIC ACID DERIVATIVES

#300
20180079723
2018-03-22

Monocyclic compound